Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP707 in Advanced Solid Tumors
NCT05037149Phase 1Completed
- Sponsor
- Sirnaomics
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of stp707 in solid tumor (6 arms), sponsored by Sirnaomics. Primary endpoints: Maximum Tolerated Dose at 28 days and Limited Dose Toxicity at 28 days. Started Nov 2021; status: completed.
02
Drugs
stp707
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05037149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037149.